This website is intended for UK patients who have been prescribed Calquence (acalabrutinib) only. For UK members of the public, please visit http://www.astrazeneca.co.uk/

This does not replace the Patient Information Leaflet, which can be found in the carton containing your medicine and should be read alongside this information.

MyCLL logo, link to the MyCLL homepage
MyCLL logo, link to the MyCLL homepage
  • Home
  • Understanding CLL
  • About Calquence
  • Managing my CLL
  • Resources
  • FAQs
calquence logoastrazeneca logo
 
MyCLL logo, link to the MyCLL homepage
  • Home
  • Understanding CLL
  • About Calquence
  • Managing my CLL
  • Resources
  • FAQs

What are you looking for today?

Understanding CLL

Learn about what CLL is, signs and symptoms, stages and treatment goals

About Calquence

Information on what Calquence is, how to take it and treatment guidance

Managing my CLL

Access daily wellness tips, support networks and help with setting goals

Magnifying glass icon representing frequently asked questions Magnifying glass icon representing frequently asked questions
RESOURCES FOR YOUR JOURNEY
View resources
Many hands stacked together to represent support Many hands stacked together to represent support
HAVE A QUESTION?
Browse FAQs

GB-82672 | November 2026

If you have any questions about your treatment, talk to your healthcare team or refer to the Patient Information Leaflet. All patient images are for illustrative purposes only.

Reporting side effects

If you get any side effects, talk to your doctor, nurse or pharmacist. This includes any possible side effects not listed in the Patient Information Leaflet. You can also report side effects directly via the Yellow Card Scheme, website: http://yellowcard.mhra.gov.uk/. By reporting side effects you can help provide more information on the safety of medicines.

Side effects can also be reported to AstraZeneca in the following ways:

Online: https://contactazmedical.astrazeneca.com

Email: Medical.InformationUK@astrazeneca.com

calquence logo

GB-80574 | November 2026

Privacy Notice Terms and Conditions Cookie Policy Contact Us
astrazeneca logo

Welcome to MyCLL

This website is intended only for UK patients who have been prescribed Calquence (acalabrutinib). This website has been produced and funded by AstraZeneca.

 

Please select the relevant option:

I am not a UK Calquence patient >